PTEN haploinsufficiency leads to prostate lesions in mouse transgenic models but not to malignant tumors, so this alteration is often combined with additional genetic changes such as Rb or p53 inactivation in tumor models to mimic more closely the clinical situation [124]. The gene discussed is RB1; the disease is neoplasm.